[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526528":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":41,"collaborators":10,"id":43,"slug":10,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Chinese Pulmonary Vascular Disease Research Group","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"PH Patients receiving targeted drugs treatment",null,"Patients with pulmonary hypertension receiving targeted drugs treatment",[13],{"name":14,"affiliation":15,"role":16},"Zhihong Liu, M.D., Ph.D","Chinese Academy of Medical Sciences, Fuwai Hospital","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","8601088396816","zhihongliufuwai@163.com",[23],{"facility":24,"status":25,"city":26,"state":10,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Center for Respiratory and Pulmonary Vascular Diseases, Fuwai hospital, CAMS & PUMC","RECRUITING","Beijing","100037","China","CN",{"type":31,"coordinates":32},"Point",[33,34],116.39723,39.9075,{"lat":34,"lon":33},[37,40],{"name":38,"role":19,"phone":39,"phoneExt":10,"email":21},"Zhihong Liu, MD,PhD","+861088396590",{"name":38,"role":16,"phone":10,"phoneExt":10,"email":10},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100526528",false,"NCT06135909","CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy","CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy","Inclusion Criteria:\n\n* Sign informed consent;\n* Between the ages of 18 and 85;\n* Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists).\n\nExclusion Criteria:\n\n* Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study;\n* Patients with malignant tumor and other diseases and life expectancy of less than half a year;\n* Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension","ALL","18 Years","85 Years",{"count":53,"type":54},5000,"ESTIMATED","5 Years","OBSERVATIONAL","CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy (CHASE Study)",[59],"Pulmonary Hypertension","2024-01-16",{"date":62,"type":63},"2024-01-18","ACTUAL",{"date":65,"type":63},"2020-01-01",{"date":67,"type":54},"2027-12-31",{"name":5,"class":6},1]